- Background: The study investigated the clinical significance of HORMAD1 overexpression and promoter hypomethylation in triple-negative breast cancers (TNBCs) regarding therapeutic response. To analyze the promoter regions and ensure precise quantification, the researchers utilized specifically designed methylation-sensitive high-resolution melting (MS-HRM) assays and calibration kits provided by Methyl Detect (Aalborg, Denmark).
-
Key Finding: The integration of standardized methylation controls—ensuring a robust detection sensitivity down to 1% methylation—allowed the research team to accurately map epigenetic regulation patterns and correlate HORMAD1 expression with clinical sensitivity to anthracycline-based chemotherapy.
-
Conclusion: The findings demonstrate that combining expression markers with reliable quantitative methylation analysis offers strong prognostic value for predicting treatment response and improving patient stratification in aggressive breast cancer subtypes.
-
Original Article & Authors: Published in Molecular Oncology (2023) by lead and corresponding researchers investigating cancer epigenetics and predictive biomarkers in oncology.
Read the full publication, see the link below ↓
